{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:31:42Z","timestamp":1791304302128,"version":"4.3.1"},"reference-count":13,"publisher":"Royal College of Psychiatrists","issue":"4","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":7763,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1996,10]]},"abstract":"\n Background<\/jats:title>\n Clozapine can cause reversible agranulocytosis and neutropenia. This study documents the occurrence of blood dyscrasias and identifies predisposing risk factors.<\/jats:p>\n <\/jats:sec>\n \n Method<\/jats:title>\n An analysis was made of the haematological, demographic, and dosage data from a central database on 6316 patients receiving clozapine over four and a half years in the UK and Ireland.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n During the study period 2.9% of the patients developed neutropenia and 0.8% developed agranulocytosis. The peak incidence of both disorders was in the first 6\u201318 weeks of treatment. Fatal agranulocytosis occurred in 0.03% of patients. After the first year of treatment the incidence of agranulocytosis significantly decreased to the order noted with some phenothiazines.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The use of a patient monitoring service kept the haematological risks associated with using clozapine within acceptable limits, particularly in view of the benefits of this medication in treatment-resistant schizophrenia.<\/jats:p>\n <\/jats:sec>","DOI":"10.1192\/bjp.169.4.483","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T01:35:17Z","timestamp":1224034517000},"page":"483-488","source":"Crossref","is-referenced-by-count":240,"title":["Neutropenia and Agranulocytosis in Patients Receiving Clozapine in the UK and Ireland"],"prefix":"10.1192","volume":"169","author":[{"given":"Karen","family":"Atkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000026003_ref5","first-page":"74","article-title":"Clozapine: negative symptoms and extrapyramidal side effects","volume":"55","author":"Kane","year":"1994","journal-title":"Journal of Clinical Psychiatry"},{"key":"S0007125000026003_ref12","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-197815020-00003"},{"key":"S0007125000026003_ref4","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"S0007125000026003_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442563"},{"key":"S0007125000026003_ref10","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/S000712500029692X","article-title":"Dimensions of outcome with clozapine","volume":"160","author":"Meltzer","year":"1992","journal-title":"British Journal of Psychiatry"},{"key":"S0007125000026003_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-7634(05)80058-2"},{"key":"S0007125000026003_ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199307153290303"},{"key":"S0007125000026003_ref2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1981.tb09853.x"},{"key":"S0007125000026003_ref9","first-page":"10","article-title":"Drug-induced neutropenia and agranulocytosis","volume":"20","year":"1993","journal-title":"Current Problems in Pharmacovigilance"},{"key":"S0007125000026003_ref13","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1991.00400030063011"},{"key":"S0007125000026003_ref6","first-page":"148","volume-title":"The Drug Aetiology of Agranulocytosis and Aplastic Anaemia","author":"Kaufman","year":"1991"},{"key":"S0007125000026003_ref8","first-page":"32","article-title":"Agranulocytosis and phenothiazines","volume":"29","author":"Mandel","year":"1986","journal-title":"Diseases of the Nervous System"},{"key":"S0007125000026003_ref7","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.4.503"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000026003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,12]],"date-time":"2019-05-12T16:29:13Z","timestamp":1557678553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000026003\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,10]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,10]]}},"alternative-id":["S0007125000026003"],"URL":"https:\/\/doi.org\/10.1192\/bjp.169.4.483","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,10]]}}}